

REMARKS/ARGUMENTS

Claims 1-21 are pending. Applicants have amended claims 1, 4, 8 and 15 to remove “solvates,” “polymorphs,” and “metabolites.”

Obviousness-Type Double Patenting

Claims 1-3 have been rejected under the doctrine of obviousness-type double patenting over claims 1-7 of U.S. Patent No. 7,399,779; claims 1-6 of U.S. Patent No. 7,288,562; claims 1-2 of U.S. Patent No. 7,446,123; and claims 1-7 of co-pending application No. 10/520,572. Applicants herewith submit Terminal Disclaimers of the term of the claims of the present application as they would extend beyond the terms of the cited U.S. Patents and co-pending application.


CONCLUSION

Applicants urge the Examiner to reconsider and withdraw the pending rejections, and respectfully request a Notice of Allowance for the pending claims at this time

Authorization is hereby given to charge any fees deemed to be due in connection with this Response to Deposit Account No. 50-0912.

Respectfully submitted,

SALMAN et al.

By: 
George E. Heibel
Reg. No. 42,648
Tel.: (609) 720-5334

Date: May 11, 2009

Correspondence Address:
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Facsimile: (609) 514-9779